On April 8, 2024, D3 Bio, Inc., a globally orientated, clinical-stage biotechnology company that focuses on the discovery, development, and registration of new medicines in oncology and immunology, announced its closing of a $62 million Series A+ financing. The financing was led by Medicxi, a leading European life sciences investment firm, with participation by existing investors Matrix Partners China and WuXi AppTec’s corporate venture fund. The funding will be allocated to expedite the development of D3 Bio’s assets through preclinical and clinical stages, with a particular focus on accelerating the global clinical trial of D3S-001, a new generation small molecule KRAS G12C inhibitor with the best-in-class potential. D3S-001 is currently in Phase II development in non-small cell lung cancer, colorectal cancer, and pancreatic cancer.

Wilson Sonsini advised existing investors, including Matrix Partners China and WuXi AppTec’s corporate venture fund, on this transaction. The Wilson Sonsini team was led by partner Jie Zhu, and included Jill Sheng, Xuchao Dong, and Yang Liao.